tirabrutinib

Overview

Second-generation covalent BTK inhibitor. Under evaluation in CNS lymphoma as a more selective alternative to ibrutinib.

Evidence in the corpus

• Flagged as an ongoing second-generation BTK inhibitor trial context for testing whether TBL1XR1-driven benefit from BTK inhibition in PCNSL generalizes beyond ibrutinib PMID:38995739.

Resistance mechanisms

• Not directly reported in the corpus.

Cancer types (linked)

• PCNSL

Sources

• PMID:38995739

This page was processed by crosslinker on 2026-04-09.